Benzinga's Top #PreMarket Losers

By: via Benzinga
Halozyme Therapeutics (NASDAQ: HALO) fell 23.73% to $8.84 in pre-market trading after the company announced the temporary halt of Phase ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.